CA2265671A1 - Inhibiteurs de metalloproteases matricielles - Google Patents

Inhibiteurs de metalloproteases matricielles Download PDF

Info

Publication number
CA2265671A1
CA2265671A1 CA002265671A CA2265671A CA2265671A1 CA 2265671 A1 CA2265671 A1 CA 2265671A1 CA 002265671 A CA002265671 A CA 002265671A CA 2265671 A CA2265671 A CA 2265671A CA 2265671 A1 CA2265671 A1 CA 2265671A1
Authority
CA
Canada
Prior art keywords
alkyl
group
methyl
defined above
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265671A
Other languages
English (en)
Inventor
Daniela Jabes
Riccardo Corigli
Francesca Abrate
Ettore Perrone
Pierluigi Bissolino
Marco Alpegiani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714548.6A external-priority patent/GB9714548D0/en
Priority claimed from GBGB9724395.0A external-priority patent/GB9724395D0/en
Application filed by Individual filed Critical Individual
Publication of CA2265671A1 publication Critical patent/CA2265671A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un composé qui est un dérivé amine représenté par la formule (I), dans laquelle W est -CONHOH ou -COOH; R¿1? et R¿2? sont chacun l'hydrogène ou un résidu organique, R¿3? est un groupe organique, Q est un groupe amide tertiaire acyclique ou cyclique, ainsi que les sels, solvates et hydrates pharmaceutiquement acceptables de ces derniers. Ces composés sont des inhibiteurs des métalloprotéases matricielles (MMP) et de la libération de facteur de nécrose tumorale alpha (TNF) par les cellules. Ils sont par conséquent utiles pour prévenir, traiter et lutter contre les maladies dans les lesquelles les MMP ou le TNF interviennent, en particulier les maladies tumorales et inflammatoires. L'invention concerne également des procédés de préparation et des compositions pharmaceutiques contenant ces composés.
CA002265671A 1997-07-10 1998-07-07 Inhibiteurs de metalloproteases matricielles Abandoned CA2265671A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9714548.6A GB9714548D0 (en) 1997-07-10 1997-07-10 Matrix metalloproteinase inhibitors
GB9714548.6 1997-07-10
GBGB9724395.0A GB9724395D0 (en) 1997-11-18 1997-11-18 Matrix metalloproteinase inhibitor
GB9724395.0 1997-11-18
PCT/EP1998/004220 WO1999002510A1 (fr) 1997-07-10 1998-07-07 Inhibiteurs de metalloproteases matricielles

Publications (1)

Publication Number Publication Date
CA2265671A1 true CA2265671A1 (fr) 1999-01-21

Family

ID=26311862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265671A Abandoned CA2265671A1 (fr) 1997-07-10 1998-07-07 Inhibiteurs de metalloproteases matricielles

Country Status (5)

Country Link
EP (1) EP0925289A1 (fr)
JP (1) JP2001500533A (fr)
AU (1) AU8858398A (fr)
CA (1) CA2265671A1 (fr)
WO (1) WO1999002510A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
DE60033809T2 (de) 1999-06-04 2007-12-06 Astrazeneca Ab Inhibitoren von metalloproteinasen
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2268301A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel urea compounds, compositions and methods of use and preparation
WO2001053269A1 (fr) * 2000-01-18 2001-07-26 The Regents Of The University Of California Catalyseurs de reaction a base de sels d'addition acides des imidazolidinones
SK287071B6 (sk) * 2000-02-21 2009-11-05 Astrazeneca Ab Deriváty N-hydroxyformamidov substituované piperidínom a piperazínom, farmaceutická kompozícia, ktorá ich obsahuje, spôsob ich prípravy a ich použitie
WO2002006227A1 (fr) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de la metalloprotease matricielle
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2002102791A1 (fr) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. Composés bicycliques de pyrrolidine
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
ATE399012T1 (de) 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
WO2004065354A1 (fr) 2003-01-17 2004-08-05 Topotarget Uk Limited Composes d'acide carbamique comprenant une liaison ester ou cetone, utilises comme inhibiteurs de l'histone desacetylase
WO2005073180A1 (fr) * 2003-12-25 2005-08-11 Kureha Corporation Derive d'acide hydroyamique et inhibiteur de generation de age contenant le derivé
EP1740168A2 (fr) * 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandines pour le traitement de pathologies oculaires
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
PL234628B1 (pl) * 2018-02-09 2020-03-31 Zachodniopomorski Univ Technologiczny W Szczecinie Sposób enancjoselektywnego prowadzenia reakcji Dielsa-Aldera
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors

Also Published As

Publication number Publication date
AU8858398A (en) 1999-02-08
EP0925289A1 (fr) 1999-06-30
JP2001500533A (ja) 2001-01-16
WO1999002510A1 (fr) 1999-01-21

Similar Documents

Publication Publication Date Title
CA2265671A1 (fr) Inhibiteurs de metalloproteases matricielles
US5763621A (en) Metalloproteinase inhibitors
EP0960108B1 (fr) Inhibiteurs de metalloproteinases matricielles
RU2151768C1 (ru) Производные уксусной кислоты
KR100432602B1 (ko) 매트릭스메탈로프로테아제억제제
AU639706B2 (en) Hydroxamic acid based collagenase inhibitors
US5908851A (en) Derivatives of succinamide and their use as metalloproteinase inhibitor
DE60127595T2 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
CA2463272C (fr) Derives de piperazine a activite antagoniste du recepteur ccr1
US20030008849A1 (en) Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors
EP0468231A2 (fr) Guanidines
EP0641779A1 (fr) Nouveaux 1-amidinopiperidines et 4-amidinomorpholines comme inhibiteurs d'aggrégation
NO313752B1 (no) Arylsulfonylaminohydroksamsyre-derivater, anvendelse derav samt farmasöytisk blanding
JP2002535382A (ja) アセチレンのα−アミノ酸に基づくスルホンアミドヒドロキサム酸ＴＡＣＥインヒビター
JP2002513408A (ja) チオールスルホンアミドヒドロキサム酸化合物
JP2002507606A (ja) チオカルボキサミド誘導体およびα４インテグリンの阻害剤としてのそれらの使用
JP2003528079A (ja) 複素環式側鎖含有メタロプロテアーゼ阻害剤
EP0895988B1 (fr) Dérivés de l'acide arylsulfonamino-hydroxamique
US20030050310A1 (en) Hydroxamic acid derivatives as proteinase inhibitors
KR20000022534A (ko) 매트릭스 메탈로프로티나아제 억제제
JP2002538136A (ja) アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤
US6482827B1 (en) Matrix metalloproteinase inhibitors
EP1005449B1 (fr) Acides 3-aryle-succinamido-hydroxamiques, leur procede de production et les medicaments contenant ces substances
KR20020038951A (ko) 베타 이치환된 메탈로프로테아제 저해제
AU732796B2 (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
FZDE Dead